In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Number 2: Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar competition, according to Samsung Bioepis’ most recent market report, ...

EST Psyence Biomedical (PBM) files to sell 3.075M common shares for holdersInvest with Confidence: Follow TipRanks' Top Wall Street ...

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for ...

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...

while stating that UnitedHealth’s pharmacy-benefit managers (PBM), who help negotiate retail drug prices and who have come under increasing public pressure for their role in setting drug prices ...

LITTLE ROCK, Ark. — High drug costs and struggling local pharmacies have become critical challenges for Arkansans. That reality is the very reason that's prompting lawmakers to take action ...

The FTC’s investigation into PBM practices began in 2022 ... “In 2024, we helped eligible patients save $1.3 billion and the median out-of-pocket payment for these patients was $5.” ...

Tuesday’s findings come on the heels of a PBM report the FTC released last year ... Cancer drugs alone made up nearly half of the $7.3 billion, the commission wrote, with multiple sclerosis ...

These companies are considered the “Big 3” in the PBM industry, controlling roughly 60 percent of the market. “The FTC staff’s second interim report finds that the three major pharmacy ...